{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:25:14Z","timestamp":1794273914849,"version":"4.9.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.omtn.2026.102873","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T17:17:48Z","timestamp":1772126268000},"page":"102873","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Delivery of monoclonal antibodies using mRNA lipid nanoparticles confers protection against SARS-CoV-2 and influenza"],"prefix":"10.1016","volume":"37","author":[{"given":"Mai N.","family":"Vu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Neil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charley","family":"Mackenzie-Kludas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyon-Xhi","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanta","family":"Subbarao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen Shi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam K.","family":"Wheatley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2026.102873_bib1","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.102873_bib2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2288-10-18","article-title":"Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model","volume":"10","author":"Coudeville","year":"2010","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.omtn.2026.102873_bib3","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0140-6736(19)30036-4","article-title":"Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study","volume":"393","author":"Gaudinski","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2026.102873_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(22)00097-0","article-title":"Nirsevimab: a promising therapy for RSV","volume":"3","author":"Venkatesan","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.omtn.2026.102873_bib5","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1016\/j.cell.2021.05.005","article-title":"Tackling COVID-19 with neutralizing monoclonal antibodies","volume":"184","author":"Corti","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2026.102873_bib6","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102873_bib7","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1056\/NEJMc2103916","article-title":"Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19","volume":"384","author":"Doria-Rose","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102873_bib8","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12967-019-1804-8","article-title":"How mRNA therapeutics are entering the monoclonal antibody field","volume":"17","author":"Van Hoecke","year":"2019","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.omtn.2026.102873_bib9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41422-022-00630-0","article-title":"Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters","volume":"32","author":"Deng","year":"2022","journal-title":"Cell Res."},{"key":"10.1016\/j.omtn.2026.102873_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113735","article-title":"The therapeutic potential of mRNA-encoded SFTSV human monoclonal antibody encapsulated lipid nanoparticle in vivo","volume":"382","author":"Lee","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.omtn.2026.102873_bib11","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-021-01573-6","article-title":"A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus","volume":"27","author":"August","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.102873_bib12","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00064-24","article-title":"Unravelling influenza correlates of protection: lessons from human A\/H1N1 Challenge","volume":"15","author":"Cox","year":"2024","journal-title":"mBio"},{"key":"10.1016\/j.omtn.2026.102873_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127175","article-title":"Mucosal immune responses to SARS-CoV-2 infection and COVID-19 vaccination","volume":"56","author":"Paul","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.omtn.2026.102873_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109822","article-title":"Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain","volume":"37","author":"Wheatley","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2026.102873_bib15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/imcb.12508","article-title":"Poor protective potential of influenza nucleoprotein antibodies despite wide prevalence","volume":"100","author":"Vanderven","year":"2022","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.omtn.2026.102873_bib16","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/19420862.2015.1008351","article-title":"Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells","volume":"7","author":"Chng","year":"2015","journal-title":"mAbs"},{"key":"10.1016\/j.omtn.2026.102873_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102547","article-title":"Deconvolution of cargo delivery and immunogenicity following intranasal delivery of mRNA lipid nanoparticle vaccines","volume":"36","author":"Vu","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.102873_bib18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.omtn.2026.102873_bib19","doi-asserted-by":"crossref","first-page":"8042","DOI":"10.1038\/s41467-023-43798-8","article-title":"A lung-selective delivery of mRNA encoding broadly neutralizing antibody against SARS-CoV-2 infection","volume":"14","author":"Tai","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.102873_bib20","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.omtn.2026.102873_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202002142","article-title":"Hemagglutinin Functionalized Liposomal Vaccines Enhance Germinal Center and Follicular Helper T Cell Immunity","volume":"10","author":"Vu","year":"2021","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.omtn.2026.102873_bib22","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.omtn.2026.102873_bib23","article-title":"mRNA-delivered neutralizing antibodies confer protection against SARS-CoV-2 variant in the lower and upper respiratory tract","author":"Hazell","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.omtn.2026.102873_bib24","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1038\/s41467-020-17409-9","article-title":"Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice","volume":"11","author":"McKay","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.102873_bib25","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1172\/JCI132779","article-title":"In vivo delivery of synthetic DNA\u2013encoded antibodies induces broad HIV-1\u2013neutralizing activity","volume":"130","author":"Wise","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtn.2026.102873_bib26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12977-018-0449-7","article-title":"Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against HIV-1","volume":"15","author":"Lin","year":"2018","journal-title":"Retrovirology"},{"key":"10.1016\/j.omtn.2026.102873_bib27","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1038\/s41596-025-01174-4","article-title":"The design, manufacture and LNP formulation of mRNA for research use","volume":"20","author":"Leighton","year":"2025","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.omtn.2026.102873_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/1547691X.2021.2020937","article-title":"Adaptation of an ELISA assay for detection of IgG2a responses against therapeutic monoclonal antibodies in a mouse immunization model","volume":"19","author":"Rane","year":"2022","journal-title":"J. Immunotoxicol."},{"key":"10.1016\/j.omtn.2026.102873_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202202595","article-title":"Engineered Ferritin Nanoparticle Vaccines Enable Rapid Screening of Antibody Functionalization to Boost Immune Responses","volume":"12","author":"Vu","year":"2023","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.omtn.2026.102873_bib30","doi-asserted-by":"crossref","first-page":"459","DOI":"10.5694\/mja2.50569","article-title":"Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia","volume":"212","author":"Caly","year":"2020","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.omtn.2026.102873_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003656","article-title":"SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants","volume":"18","author":"Tea","year":"2021","journal-title":"PLoS Med."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126000442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126000442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:14:43Z","timestamp":1794273283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253126000442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2162253126000442"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2026.102873","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delivery of monoclonal antibodies using mRNA lipid nanoparticles confers protection against SARS-CoV-2 and influenza","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2026.102873","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102873"}}